Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

BioLineRx (BLRX) Income towards Parent Company: 2012-2024

Historic Income towards Parent Company for BioLineRx (BLRX) over the last 13 years, with Dec 2024 value amounting to -$11.3 million.

  • BioLineRx's Income towards Parent Company rose 45.04% to -$2.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$7.7 million, marking a year-over-year increase of 80.04%. This contributed to the annual value of -$11.3 million for FY2024, which is 76.25% up from last year.
  • According to the latest figures from FY2024, BioLineRx's Income towards Parent Company is -$11.3 million, which was up 76.25% from -$47.5 million recorded in FY2023.
  • Over the past 5 years, BioLineRx's Income towards Parent Company peaked at -$11.3 million during FY2024, and registered a low of -$47.5 million during FY2023.
  • For the 3-year period, BioLineRx's Income towards Parent Company averaged around -$28.6 million, with its median value being -$27.0 million (2022).
  • Its Income towards Parent Company has fluctuated over the past 5 years, first tumbled by 76.03% in 2023, then surged by 76.25% in 2024.
  • BioLineRx's Income towards Parent Company (Yearly) stood at -$21.3 million in 2020, then fell by 11.61% to -$23.8 million in 2021, then dropped by 13.58% to -$27.0 million in 2022, then slumped by 76.03% to -$47.5 million in 2023, then spiked by 76.25% to -$11.3 million in 2024.